Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States.
| Revenue (Most Recent Fiscal Year) | $1.24B |
| Net Income (Most Recent Fiscal Year) | $210.00M |
| PE Ratio (Current Year Earnings Estimate) | 11.18 |
| PE Ratio (Trailing 12 Months) | 12.44 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 3.54 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 13.77 |
| Pre-Tax Margin (Trailing 12 Months) | 22.85% |
| Net Margin (Trailing 12 Months) | 19.44% |
| Return on Equity (Trailing 12 Months) | -219.26% |
| Return on Assets (Trailing 12 Months) | 29.40% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.86 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.66 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 1.59 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-1.18 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.96 |
| Earnings per Share (Most Recent Fiscal Year) | $2.50 |
| Diluted Earnings per Share (Trailing 12 Months) | $1.95 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 121.92M |
| Free Float | 121.02M |
| Market Capitalization | $4.57B |
| Average Volume (Last 20 Days) | 2.50M |
| Beta (Past 60 Months) | 0.90 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.74% |
| Percentage Held By Institutions (Latest 13F Reports) | 60.33% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |